Apple secures FDA clearance for hearing aid software on AirPods Pro

A patient sitting on a household sofa taps a mobile phone screen while listening to a sequence of faint tones through standard wireless earbuds. Within ten minutes, this self-administered assessment generates a personalized hearing profile, replicating a process that previously required a clinical sound booth and specialized diagnostic equipment.

This workflow is now a regulated medical intervention. The United States Food and Drug Administration has granted marketing clearance for Apple's Hearing Aid Feature, a software-only medical product designed for the AirPods Pro 2. This decision marks the first time the regulator has authorized an over the counter hearing aid software application on a mass-market consumer audio platform. The software allows standard consumer earbuds to function as a self-fitting, clinical-grade hearing aid for adults with perceived mild to moderate hearing impairment.

According to regulatory documentation from the Food and Drug Administration, the clearance was supported by a clinical study of 118 subjects with perceived mild to moderate hearing loss. The trial, conducted across multiple clinical sites in the United States, compared the acoustic settings generated by the self-fitting software against professional fittings performed by licensed audiologists using standard real-ear measurements.

The clinical data demonstrated that the software-driven self-fitting strategy achieved comparable outcomes to professional custom fittings. Participants reported equivalent levels of perceived benefit, speech understanding in both quiet and noisy environments, and overall sound quality. No serious adverse events related to the use of the software or hardware were reported during the evaluation period. Once configured, the software automatically applies a customized amplification profile to environmental sounds, utilizing directional microphones and active noise reduction to improve speech clarity.

Market and clinical significance

This regulatory milestone addresses a long-standing public health gap in auditory care. Data from the National Institute on Deafness and Other Communication Disorders indicate that approximately 30 million adults in the United States could benefit from using hearing aids. However, only about 20 percent of those who could benefit from an assistive device currently use one. Two primary barriers have historically restricted adoption: financial cost and social stigma.

Traditional prescription hearing aids often cost between 3,000 and 6,000 dollars per pair, expenses that are rarely covered fully by commercial insurance and are excluded from standard Medicare benefits. By contrast, the compatible consumer earbuds retail for 249 dollars, with the diagnostic and therapeutic software delivered via a free firmware update. This pricing structure lowers the financial threshold for auditory assistance by several thousand dollars.

The second barrier is psychological. Traditional hearing aids carry a persistent clinical stigma, which contributes to patients delaying treatment for an average of seven to ten years after first noticing hearing loss. Wireless consumer earbuds, by contrast, are culturally ubiquitous. By embedding clinical utility inside a mainstream consumer product, the intervention leverages existing social norms to bypass the stigma of medical devices, potentially accelerating early-stage adoption.

From a clinical perspective, untreated mild to moderate hearing loss is associated with accelerated cognitive decline, social isolation, depression, and an increased risk of physical falls. By lowering the entry barriers, clinicians have an opportunity to intervene earlier in the course of auditory decline, potentially mitigating these systemic health risks before they require more resource-intensive medical interventions.

Operator perspective and operational hurdles

For healthcare system operators and clinical audiologists, this model shifts the professional role from equipment dispensing to clinical management. Rather than spending valuable clinic time on initial device selection and basic fitting for mild cases, audiologists can focus on patients with complex, severe, or asymmetric hearing loss who require bespoke prescription hardware and hands-on rehabilitative care.

However, several operational challenges remain for patients transitioning to consumer hardware. The first is battery life. Traditional hearing aids use specialized zinc-air or rechargeable lithium-ion batteries that provide between 12 and 30 hours of continuous use on a single charge. The consumer earbuds used here deliver approximately six hours of active battery life per charge with the hearing assistant features enabled. This limited duration requires users to adopt an episodic use pattern, wearing the devices during meetings, social events, or television viewing, rather than the continuous, all-day wear typical of traditional medical devices.

The second challenge is the physical and acoustic design of the hardware. Traditional hearing aids are often open-fit, meaning they allow natural low-frequency sounds to enter the ear canal directly, avoiding the occluded or plugged feeling that alters the sound of the user's own voice. The consumer earbuds rely on a sealed silicone ear tip to manage noise cancellation and audio delivery, which can produce a more noticeable occlusion effect for some users.

Finally, clinical operators must prepare for a shift in patient workflows. When patients can self-screen and self-fit their devices, the traditional entry point to audiological care is bypassed. For practices that rely on the high margins of hardware dispensing, this transition requires a strategic shift toward billing for clinical expertise, complex diagnostics, and cognitive rehabilitation services.